Anti-CGRP monoclonal antibody therapy in patients with migraine can reduce headache burden and stabilize retinal and optic nerve changes.

With the Tear Film And Ocular Surface Society’s Dry Eye Workshop update comes a more nuanced definition of dry eye disease.